World Pharma Today: 2022 biopharma trends roundtable

Scroll Down

The potential of both mRNA technologies and lipid nanoparticle (LNPs) have been highlighted throughout the COVID-19 pandemic. With the upsurge in the mRNA technologies in clinical pipelines globally, 2022 will be a year dominated by mRNA-based products.

In this commentary, Bill Vincent, Founder and Executive Chairman at Genezen, highlights mRNA technologies as the innovation disrupting the biopharmaceutical industry and discusses how LNPs could further impact drug product development in future.

Read the full article here: 2022 innovations to look out for in the pharma arena

You may also be interested in...

Genezen delivers next phase of cGMP…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen, Monon Bioventures, and Purdue University…

Glioblastoma is one of the most aggressive types of cancer, affecting...

Read more

How can pseudotyping gammaretrovirus impact manufacturing?

Designing the plasmids that will be transfected into producer cells in...

Read more

ARM A-Cell: New guidance incorporates quality…

Lentiviruses are an essential tool for many cell and gene therapies...

Read more